Radiopharm Theranostics Limited Sponsored ADR RADX 深 沪
等待开盘 10-07 09:30:00 美东时间
1.185
-0.085
-6.69%
华盛通- 最 高1.28
- 今 开1.28
- 成交量 5.63万股
- 最 低 1.16
- 昨 收 1.27
- 总市值 1729.13万
- 52周最高 16.25
- 市盈率 静 --
- 换手率 0.39%
- 52周最低 1.00
- 委 比 85.41%
- 总股本 1459.18万
- 历史最高 50.82
- 量 比 2.17
- 振 幅 9.45%
- 历史最低 1.00
- 每 手 1
- 风险率 1.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Radiopharm Secures FDA Guidance as RAD101 Advances Toward Pivotal Brain Metastases Trial
An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now avail...
10-05 06:12
Radiopharm Theranostics Options Registry Reveals Strong Institutional Concentration
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an update. Radiophar...
09-17 08:57
Radiopharm Theranostics Completes A$3 Million Share Purchase Plan
Radiopharm Theranostics Limited ( ($AU:RAD) ) has issued an update. Radiopharm ...
09-17 08:27
Radiopharm Theranostics Shares Data From Phase 1 Imaging Trial of RAD 301 In Healthy Volunteers And Subjects With Pancreatic Ductal Adenocarcinoma
RAD301 is a peptide-based molecule bound to Gallium-68 (Ga-68) that targets αvβ6-integrin, a cellular marker for tumor invasion and metastatic growth, the expression of which correlates with decreased survival in several carcinomas. The αvβ6-integrin receptor is found in high density on most pancrea...
09-09 19:13
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial
Radiopharm Theranostics received a positive recommendation from the Data Safety and Monitoring Committee to advance its RAD202 Phase 1 trial to the next dose level of 180mCi in patients with HER2-positive advanced solid tumors. The recommendation is based on favorable safety data from previous studies, including a diagnostic trial in HER2-positive breast cancer patients that demonstrated clinical proof-of-concept. RAD202, a monoclonal antibody ta...
08-20 11:00
Radiopharm Theranostics Reports Business Update
Radiopharm Theranostics reported positive Phase 2b results for imaging agent RAD 101, with 93% of evaluable patients achieving the primary endpoint. The company plans to initiate a Phase 3 registrational trial for RAD 101 in Q4 2026. Additionally, the company raised approximately $12.5 million through an institutional offer and launched a $6 million Share Purchase Plan. RAD 204 showed promising early clinical signs in a Phase 1 trial, with the fi...
07-31 11:00
Radiopharm Theranostics Sets Target Market for Free Attaching Options
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
07-30 14:48
Radiopharm Theranostics Announces Updated Clinical Results From First Two Patients In Third Cohort Of RAD204; First RECIST-Confirmed Durable Partial Response At Current Highest Dose Level #3, With Patient Progression Free Beyond Seven Months
Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far
07-22 19:10
Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases
Radiopharm Theranostics announced positive results from its Phase 2b trial of RAD101 for diagnosing suspected recurrent brain metastases. The trial showed 93% concordance between RAD101 PET and MRI imaging, meeting the primary endpoint. Sensitivity was 86% in 14 patients with follow-up data, with specificity results expected in Q4 2026. The company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026. The imaging Brain Metastases ...
07-22 11:00
Radiopharm Secures A$5.9m R&D Tax Refund to Fuel Cancer Radiopharmaceutical Pipeline
Radiopharm Theranostics Limited ( ($AU:RAD) ) has provided an announcement. Rad...
07-03 13:37
